
Coagulation Factor Deficiency Market - US To Have The Lion's Share Among The 7MM's Delveinsight
Coagulation Factor Deficiency Market Report Metrics |
Details |
Study Period |
2020–2034 |
Coverage |
7MM [the United States, the EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan]. |
Coagulation Factor Deficiency Market Size |
USD 13.5 Billion |
Key Coagulation Factor Deficiency Companies |
Novo Nordisk, Spark Therapeutics, Sanofi, Alnylam Pharmaceuticals, Pfizer, Biotest AG, Centessa Pharmaceuticals (Apcintex), Staidson Biopharma Inc., Ultragenyx Pharmaceutical, Bayer, and others |
Key Pipeline Coagulation Factor Deficiency Therapies |
Concizumab (NN7415), RG6357 (SPK-8011), Fitusiran (ALN-AT3, SAR-439774), Marstacimab (PF-06741086), NNC0365-3769 A (MIM8), BT524, SERPINPC, STSP-0601, BAY2599023 (DTX201 AAV FVIII), and others |
Scope of the Coagulation Factor Deficiency
Market Report
-
Therapeutic Assessment: Coagulation Factor Deficiency
current marketed and emerging therapies Coagulation Factor Deficiency
Market Dynamics:
Key Market Forecast Assumptions of Emerging Coagulation Factor Deficiency
Drugs and Market Outlook Competitive Intelligence Analysis:
SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Coagulation Factor Deficiency Market Access and Reimbursement
Download the report to understand which factors are driving coagulation factor deficiency market trends
@
Coagulation Factor Deficiency Market Trends
Table of Contents
1 |
KEY INSIGHTS |
2 |
REPORT INTRODUCTION |
3 |
COAGULATION FACTOR DEFICIENCY MARKET OVERVIEW AT A GLANCE |
3.1 |
MARKET SHARE (%) DISTRIBUTION OF COAGULATION FACTOR DEFICIENCY IN 2020 |
3.2 |
MARKET SHARE (%) DISTRIBUTION OF COAGULATION FACTOR DEFICIENCY IN 2034 |
4 |
EXECUTIVE SUMMARY OF COAGULATION FACTOR DEFICIENCY |
5 |
KEY EVENTS |
6 |
EPIDEMIOLOGY AND MARKET METHODOLOGY |
7 |
COAGULATION FACTOR DEFICIENCY DISEASE – OVERVIEW |
7.1 |
INTRODUCTION |
7.2 |
PROCESS OF CLOTTING |
7.3 |
TYPE OF CLOTTING FACTORS AND THEIR FUNCTIONS |
7.4 |
MECHANISM |
7.5 |
TYPE OF COAGULATION FACTOR DEFICIENCY |
7.5.1 |
Coagulation Factor I Deficiency (Fibrinogen) |
7.5.1.1 |
Afibrinogenemia |
7.5.1.2 |
Hypofibrinogenemia |
7.5.1.3 |
Dysfibrinogeneima |
7.5.1.4 |
Hypodysfibrinogenemia |
7.5.2 |
Coagulation Factor II Deficiency (Prothrombin) |
7.5.3 |
Coagulation Factor V Deficiency |
7.5.4 |
Coagulation Factor VII Deficiency |
7.5.5 |
Coagulation Factor VIII Deficiency (Hemophilia A) |
7.5.6 |
Coagulation Factor IX Deficiency (Hemophilia B) |
7.5.7 |
Coagulation Factor X Deficiency |
7.5.8 |
Coagulation Factor XI Deficiency (Hemophilia C) |
7.5.9 |
Coagulation Factor XII Deficiency |
7.5.10 |
Coagulation Factor XIII Deficiency |
7.5.11 |
Von Willebrand Disease |
7.6 |
SYMPTOMS ASSOCIATED WITH DEFICIENCY OF COAGULATION FACTORS |
7.7 |
CAUSES OF COAGULATION FACTOR DEFICIENCY DISEASE |
7.7.1 |
Inherited (Genetic) Causes: |
7.7.2 |
Acquired Causes: |
7.8 |
TESTING |
7.9 |
DIAGNOSIS |
7.9.1 |
Diagnosis of Hemophilia A |
7.9.1.1 |
Establishing the Diagnosis |
7.9.1.2 |
Molecular Genetic Testing |
7.9.1.3 |
Screening Tests |
7.9.1.4 |
Clotting Factor Tests |
7.9.1.5 |
Inhibitor Testing |
7.9.2 |
Diagnosis of Hemophilia B |
7.9.3 |
Diagnosis of Von Willebrand disease |
7.1 |
TREATMENT AND MANAGEMENT |
7.10.1 |
Treatment |
7.10.1.1 |
Non replacement therapies |
7.10.1.2 |
Replacement therapies |
7.10.2 |
Management |
7.10.2.1 |
Healthy lifestyle |
7.10.2.2 |
Dental care |
7.10.2.3 |
Vaccinations |
7.10.2.4 |
Disease management in the case of females |
8 |
EPIDEMIOLOGY AND PATIENT POPULATION |
8.1 |
ASSUMPTIONS AND RATIONALE: 7MM |
8.2 |
KEY FINDINGS |
8.3 |
Total Diagnosed Prevalence of Coagulation Factor Deficiency in the 7mm |
8.4 |
Factor-Specific Prevalence of Coagulation Factor Deficiency in the 7mm |
8.5 |
THE UNITED STATES |
8.5.1 |
Total Diagnosed Prevalence of Coagulation Factor Deficiency in the United States |
8.5.2 |
Factor-specific Prevalence of Coagulation Factor Deficiency in the United States |
8.6 |
EU4 AND THE UK |
8.6.1 |
Total Diagnosed Prevalence of Coagulation Factor Deficiency in the EU4 and the UK |
8.6.2 |
Factor-specific Prevalence of Coagulation Factor Deficiency in the EU4 and the UK |
8.7 |
JAPAN |
8.7.1 |
Total Diagnosed Prevalence of Coagulation Factor Deficiency in the Japan |
8.7.2 |
Factor-specific Prevalence of Coagulation Factor Deficiency in the Japan |
9 |
PATIENT JOURNEY |
10 |
MARKETED THERAPIES |
10.1 |
KEY CROSS |
10.2 |
ESPEROCT (N8-GP; TUROCTOCOG ALFA PEGOL): NOVO NORDISK |
10.2.1 |
Product Description |
10.2.2 |
Regulatory Milestones |
10.2.3 |
Other Developmental Activities |
10.2.4 |
RecentClinical Development |
10.2.4.1 |
Clinical Trials Information |
10.2.5 |
Safety and efficacy |
10.2.5.1 |
Summary of Pivotal Trials |
10.2.6 |
Product Profile |
10.3 |
JIVI (FORMERLY BAY94-9027): BAYER |
10.3.1 |
Product Description |
10.3.2 |
Regulatory Milestones |
10.3.3 |
Other Developmental Activities |
10.3.4 |
Recent Clinical Development |
10.3.4.1 |
Clinical Trials Information |
10.3.5 |
Safety and efficacy |
10.3.5.1 |
Summary of Pivotal Trials |
10.3.6 |
Product Profile |
10.4 |
WILATE: OCTAPHARMA |
10.4.1 |
Product Description |
10.4.2 |
Regulatory Milestones |
10.4.3 |
Recent Clinical Development |
10.4.3.1 |
Clinical Trials Information |
10.4.4 |
Safety and Efficacy |
10.4.4.1 |
Summary of Pivotal Trials |
10.4.5 |
Product Profile |
10.5 |
ADYNOVATE (ADYNOVI; BAX 855): TAKEDA |
10.5.1 |
Product Description |
10.5.2 |
Regulatory Milestones |
10.5.3 |
Other Developmental Activities |
10.5.4 |
Recnt Clinical Development |
10.5.4.1 |
Clinical Trials Information |
10.5.5 |
Safety and efficacy |
10.5.5.1 |
Summary of Pivotal Trials |
10.5.6 |
Product Profile |
10.6 |
ELOCTATE [ELOCTA (EFMOROCTOCOG ALFA)]: SANOFI/SOBI |
10.6.1 |
Product Description |
10.6.2 |
Regulatory Milestones |
10.6.3 |
Other Developmental Activities |
10.6.4 |
Safety and efficacy |
10.6.4.1 |
Summary of Pivotal Trials |
10.6.5 |
Product Profile |
10.7 |
AFSTYLA (LONOCTOCOG ALFA): CSL BEHRING |
10.7.1 |
Product Description |
10.7.2 |
Regulatory Milestones |
10.7.3 |
Other Developmental Activities |
10.7.4 |
Safety and efficacy |
10.7.4.1 |
Summary of Pivotal Trials |
10.7.5 |
Product Profile |
10.8 |
NUWIQ (SIMOCTOCOG ALFA): OCTAPHARMA |
10.8.1 |
Product Description |
10.8.2 |
Regulatory Milestone |
10.8.3 |
Other Developmental Activities |
10.8.4 |
Safety and Efficacy |
1.1.1.1 |
Summary of Pivotal Clinical trial |
10.8.5 |
Product Profile |
10.9 |
KOVALTRY (BAY 81-8973): BAYER |
10.9.1 |
Product Description |
10.9.2 |
Regulatory Milestone |
10.9.3 |
Other Developmental Activity |
10.9.4 |
Safety and Efficacy |
10.9.4.1 |
Summary of Pivotal Clinical Trial |
10.9.5 |
Product Profile |
10.10 |
OBIZUR: TAKEDA |
10.10.1 |
Product Description |
10.10.2 |
Regulatory Milestones |
10.10.3 |
Other Developmental Activities |
10.10.4 |
Recent Clinical Development |
10.10.4.1 |
Clinical trials information |
10.10.5 |
Safety and Efficacy |
10.10.5.1 |
Summary of Pivotal Trials |
10.10.6 |
Product Profile |
10.11 |
KOGENATE FS (OCTOCOG ALFA): BAYER |
10.11.1 |
Product Description |
10.11.2 |
Regulatory Milestones |
10.11.3 |
Other Developmental Activities |
10.11.4 |
Safety and Efficacy |
10.11.4.1 |
Summary of Pivotal Trials |
10.11.5 |
Product Profile |
10.12 |
XYNTHA (REFACTO AF): PFIZER |
10.12.1 |
Product Description |
10.12.2 |
Regulatory Milestones |
10.12.3 |
Other Developmental Activities |
10.12.4 |
Safety and Efficacy |
10.12.4.1 |
Summary of Pivotal Trials |
10.12.5 |
Product Profile |
10.13 |
FEIBA: TAKEDA |
10.13.1 |
Product Description |
10.13.2 |
Regulatory Milestones |
10.13.3 |
Other Developmental Activities |
10.13.4 |
Recent Clinical Developmen |
10.13.4.1 |
Clinical trials information |
10.13.5 |
Safety and Efficacy |
10.13.5.1 |
Summary of Pivotal Trials |
10.13.6 |
Product Profile |
10.14 |
HEMLIBRA (EMICIZUMAB-KXWH): CHUGAI/ GENENTECH/ROCHE |
10.14.1 |
Product Description |
10.14.2 |
Regulatory Milestones |
10.14.3 |
Other Developmental Activities |
10.15 |
SEVENFACT [COAGULATION FACTOR VIIA (RECOMBINANT)-JNCW]: HEMA BIOLOGICS/LFB PHARMACEUTICALS |
10.15.1 |
Product Description |
10.15.2 |
Regulatory Milestones |
10.15.3 |
Other Developmental Activities |
10.15.4 |
Recent Clinical Development |
10.15.4.1 |
Clinical trials information |
10.15.5 |
Safety and Efficacy |
10.15.5.1 |
Summary of Pivotal Trial |
10.15.6 |
Product Profile |
10.16 |
HEMGENIX (ETRANACOGENE DEZAPARVOVEC): CSL BEHRING/UNIQURE |
10.16.1 |
Product Description |
10.16.2 |
Regulatory Approval |
10.16.3 |
Other Development Activities |
10.16.4 |
Recent Clinical Development |
10.16.5 |
Safety and Efficacy |
10.16.6 |
Product Profile |
10.17 |
REBINYN (NONACOG BETA PEGOL): NOVO NORDISK |
10.17.1 |
Product Description |
10.17.2 |
Regulatory Milestones |
10.17.3 |
Other Developmental Activities |
10.17.4 |
Recent Clinical Development |
10.17.4.1 |
Clinical Trials Information |
10.17.5 |
Safety and Efficacy |
10.17.5.1 |
Summary of Pivotal Trials |
10.17.6 |
Product Profile |
10.18 |
IDELVION: CSL BEHRING |
10.18.1 |
Product Description |
10.18.2 |
Regulatory Milestones |
10.18.3 |
Other Developmental Activities |
10.18.4 |
Safety and efficacy |
10.18.4.1 |
Summary of Pivotal Trial |
10.18.5 |
Product Profile |
10.19 |
ALPROLIX: SANOFI /BIOVERATIV THERAPEUTICS/SOBI |
10.19.1 |
Product Description |
10.19.2 |
Regulatory Milestones |
10.19.3 |
Other Developmental Activities |
10.19.4 |
Safety and Efficacy |
10.19.4.1 |
Summary of Pivotal Trial |
10.19.5 |
Product Profile |
10.2 |
IXINITY (TRENONACOG ALFA): MEDEXUS PHARMACEUTICALS/APTEVO THERAPEUTICS |
10.20.1 |
Product Description |
10.20.2 |
Regulatory Milestones |
10.20.3 |
Other Developmental Activities |
10.20.4 |
Safety and Efficacy |
10.20.4.1 |
Summary of Pivotal Trials |
10.20.5 |
Product Profile |
10.21 |
RIXUBIS: TAKEDA (SHIRE/BAXTER) |
10.21.1 |
Product Description |
10.21.2 |
Regulatory Milestones |
10.21.3 |
Other Developmental Activities |
10.21.4 |
Safety and Efficacy |
10.21.4.1 |
Summary of Pivotal Trial |
10.21.5 |
Product Profile |
10.22 |
VONVENDI: SHIRE |
10.22.1 |
Product Description |
10.22.2 |
Mechanism of Action |
10.22.3 |
Regulatory Milestones |
10.22.4 |
Advantages and Disadvantages |
10.22.5 |
Recent Clinical Development |
10.22.5.1 |
Clinical Trials Information |
10.22.6 |
Safety and Efficacy |
10.22.7 |
Product Profile |
10.23 |
HUMATE-P/HAEMATE P: CSL BEHRING |
10.23.1 |
Product Description |
10.23.2 |
Mechanism of Action |
10.23.3 |
Regulatory Milestones |
10.23.4 |
Advantages and Disadvantages |
10.23.5 |
Safety and Efficacy |
10.23.6 |
Product Profile |
10.24 |
ALPHANATE: GRIFOLS BIOLOGICAL INC. |
10.24.1 |
Product Description |
10.24.2 |
Mechanism of Action |
10.24.3 |
Regulatory Milestones |
10.24.4 |
Advantages and Disadvantages |
10.24.5 |
Safety and Efficacy |
10.24.6 |
Product Profile |
10.25 |
COAGADEX: BIO PRODUCTS LABORATORY |
10.25.1 |
Product Description |
10.25.2 |
Regulatory Milestones |
10.25.3 |
Other Developmental Activities |
10.25.4 |
Pivotal Clinical Trial |
10.25.4.1 |
Summary of Pivotal Clinical Trials |
10.25.5 |
Safety and Efficacy |
10.25.6 |
Product Profile |
10.26 |
ANDEXXA: ALEXION ASTRAZENECA RARE DISEASE |
10.26.1 |
Product Description |
10.26.2 |
Regulatory Milestones |
10.26.3 |
Other Developmental Activities |
10.26.4 |
Pivotal Clinical Trial |
1.1.1.2 |
Summary of Pivotal Clinical Trials |
10.26.5 |
Safety and Efficacy |
10.26.6 |
Product Profile |
10.27 |
KCENTRA: CSL BEHRING |
10.27.1 |
Product Description |
10.27.2 |
Regulatory Milestones |
10.27.3 |
Other Developmental Activities |
10.27.4 |
Ongoing Current Clinical Pipeline Activity |
10.27.5 |
Pivotal Clinical Trial |
10.27.5.1 |
Summary of Pivotal Clinical Trials |
10.27.6 |
Safety and Efficacy |
10.27.7 |
Product Profile |
10.28 |
TRETTEN® (CATRIDECACOG): NOVONORDISK |
10.28.1 |
Product Description |
10.28.2 |
Regulatory Milestones |
10.28.3 |
Pivotal Clinical Trial |
10.28.4 |
Safety and Efficacy |
10.28.5 |
Product Profile |
10.29 |
OCTAPLEX: OCTAPHARMA |
10.29.1 |
Product Description |
10.29.2 |
Regulatory Milestones |
10.29.3 |
Other Developmental Activities |
10.29.4 |
Recent Clinical Development |
10.29.5 |
Pivotal Clinical Trial |
10.29.6 |
Safety and Efficacy |
10.29.7 |
Product Profile |
10.3 |
RIASTAP: CSL BEHRING |
10.30.1 |
Product Description |
10.30.2 |
Regulatory Milestones |
10.30.3 |
Other Developmental Activities |
10.30.4 |
Pivotal Clinical Trial |
10.30.5 |
Safety and Efficacy |
10.30.6 |
Product Profile |
10.31 |
ROCTAVIAN (VALOCTOCOGENE ROXAPARVOVEC): BIOMARIN PHARMACEUTICAL |
10.31.1 |
Product Description |
10.31.2 |
Regulatory Milestone |
10.31.3 |
Other developmental activities |
10.31.4 |
Recent clinical developmental activities |
10.31.5 |
Safety and efficacy |
10.31.6 |
Product Profile |
10.32 |
ALTUVIIIO (EFANESOCTOCOG ALFA) (RFVIIIFC-VWF-XTEN): SANOFI |
10.32.1 |
Product Description |
10.32.2 |
Regulatory Milestone |
10.32.3 |
Other developmental activity |
10.32.4 |
Recent Clinical development |
10.32.4.1 |
Clinical trial information |
10.32.5 |
Safety and efficacy |
10.32.6 |
Product Profile |
11 |
EMERGING DRUGS |
11.1 |
KEY CROSS |
11.2 |
CONCIZUMAB (NN7415): NOVO NORDISK |
11.2.1 |
Product description |
11.2.2 |
Other developmental activities |
11.2.3 |
Clinical development Activities |
11.2.3.1 |
Clinical trial information |
11.2.4 |
Safety and efficacy |
11.3 |
FIDANACOGENE ELAPARVOVEC: PFIZER/SPARK THERAPEUTICS |
11.3.1 |
Product Description |
11.3.2 |
Other Developmental Activities |
11.3.3 |
Clinical Developmental Activities |
11.3.3.1 |
Clinical Trials Information |
11.3.4 |
Safety and Efficacy |
11.4 |
RG6357 (SPK-8011): ROCHE (SPARK THERAPEUTICS) |
11.4.1 |
Product description |
11.4.2 |
Other developmental activity |
11.4.3 |
Clinical development Activities |
11.4.3.1 |
Clinical trial information |
11.4.4 |
Safety and efficacy |
11.5 |
FITUSIRAN (ALN-AT3, SAR-439774): SANOFI (GENZYME)/ALNYLAM PHARMACEUTICALS |
11.5.1 |
Product description |
11.5.2 |
Other developmental activity |
11.5.3 |
Clinical development Activities |
11.5.3.1 |
Clinical trial information |
11.5.4 |
Safety and efficacy |
11.6 |
MARSTACIMAB (PF-06741086): PFIZER |
11.6.1 |
Product description |
11.6.2 |
Other developmental activities |
11.6.3 |
Clinical development Activities |
11.6.3.1 |
Clinical trial information |
11.6.4 |
Safety and efficacy |
11.7 |
GIROCTOCOGENE FITELPARVOVEC (SB-525 OR PF-07055480): PFIZER/SANGAMO THERAPEUTICS |
11.7.1 |
Product description |
11.7.2 |
Other developmental activity |
11.7.3 |
Clinical development Actvities |
11.7.3.1 |
Clinical trial information |
11.7.4 |
Safety and efficacy |
11.8 |
NNC0365-3769 A (MIM8): NOVO NORDISK A/S |
11.8.1 |
Product description |
11.8.2 |
Other developmental activity |
11.8.3 |
Clinical development Activities |
11.8.3.1 |
Clinical trial information |
11.8.4 |
Safety and efficacy |
11.9 |
BT524: BIOTEST AG |
11.9.1 |
Product Description |
11.9.2 |
Other Developmental Activities |
11.9.3 |
Clinical Development Activities |
11.9.3.1 |
Clinical Trials Information |
11.9.4 |
Safety and Efficacy |
11.10 |
SERPINPC: CENTESSA PHARMACEUTICALS (APCINTEX) |
11.10.1 |
Product description |
11.10.2 |
Other developmental activities |
11.10.3 |
Clinical development Activities |
11.10.3.1 |
Clinical trial information |
11.10.4 |
Safety and efficacy |
11.11 |
STSP-0601: STAIDSON BIOPHARMA INC. |
11.11.1 |
Product Description |
11.11.2 |
Clinical Development Activities |
11.11.2.1 |
Clinical Trials Information |
11.11.3 |
Safety and Efficacy |
11.12 |
MARZEPTACOG ALFA: GC BIOPHARMA |
11.12.1 |
Product Description |
11.12.2 |
Other Developmental Activities |
11.12.3 |
Clinical Development Activities |
11.12.3.1 |
Clinical Trials Information |
11.12.4 |
Safety and Efficacy |
11.13 |
AB023: ARONORA, INC. |
11.13.1 |
Product Description |
11.13.2 |
Other Developmental Activities |
11.13.3 |
Clinical Development Activities |
11.13.3.1 |
Clinical Trials Information |
11.13.4 |
Safety and Efficacy |
11.14 |
BAY2599023 (DTX201 AAV FVIII): BAYER/ULTRAGENYX PHARMACEUTICAL |
11.14.1 |
Product description |
11.14.2 |
Other developmental activity |
11.14.3 |
Clinical development Activities |
11.14.3.1 |
Clinical trial information |
11.14.4 |
Safety and efficacy |
11.15 |
OPK88005 (FACTOR VIIA-CTP): OPKO HEALTH, INC. |
11.15.1 |
Product Description |
11.15.2 |
Other Developmental Activities |
11.15.3 |
Clinical Development Activities |
11.15.3.1 |
Clinical Trials Information |
11.15.4 |
Safety and Efficacy |
12 |
COAGULATION FACTOR DEFICIENCY: SEVEN MAJOR MARKET ANALYSIS |
12.1 |
KEY FINDINGS |
12.2 |
MARKET OUTLOOK |
12.3 |
KEY MARKET FORECAST ASSUMPTIONS |
12.4 |
TOTAL MARKET SIZE OF COAGULATION FACTOR DEFICIENCY IN THE 7MM |
12.5 |
UNITED STATES MARKET SIZE |
12.5.1 |
Total Market Size of Coagulation Factor Deficiency in the United States |
12.6 |
EU4 AND THE UK MARKET SIZE |
12.6.1 |
Total Market Size of Coagulation Factor Deficiency in the EU4 and the UK |
12.7 |
JAPAN |
12.7.1 |
Total Market Size of Coagulation Factor Deficiency in Japan |
13 |
MARKET ACCESS AND REIMBURSEMENT |
13.1 |
HEMOPHILIA A |
13.1.1 |
The US |
13.1.1.1 |
Current Therapies |
13.1.2 |
HAS Assessment for Some Other Therapies |
13.1.3 |
HTA Assessment of Hemlibra by NHS and IQWiG |
13.1.4 |
IQWIG Assessment for Some Other Therapies |
13.1.5 |
Future Therapies: Gene Therapy |
13.2 |
HEMOPHILIA B |
13.2.1 |
Access and Reimbursement Overview for Current and Future Therapies |
13.2.2 |
NICE Assessment |
13.2.3 |
IQWIG Assessment |
13.2.4 |
HAS Assessment |
13.3 |
CLOTTING FACTORS |
13.3.1 |
The US |
13.3.1.1 |
CMS |
13.3.2 |
UK (NHS) |
13.3.3 |
EU (HTA Assessment) |
13.3.3.1 |
IQWIG |
13.3.3.2 |
AIFA |
13.3.4 |
Japan |
14 |
UNMET NEEDS |
15 |
SWOT ANALYSIS |
16 |
KOL VIEWS |
17 |
APPENDIX |
17.1 |
BIBLIOGRAPHY |
17.2 |
REPORT METHODOLOGY |
18 |
DELVEINSIGHT CAPABILITIES |
19 |
DISCLAIMER |
20 |
ABOUT DELVEINSIGHT |
Related Reports
Coagulation Factor Deficiency Epidemiology Forecast
Coagulation Factor Deficiency Epidemiology Forecast – 2032
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the coagulation factor deficiency epidemiology trends.
Coagulation Factor Deficiency Pipeline
Coagulation Factor Deficiency Pipeline Insight – 2024
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key
coagulation factor deficiency companies, including SymBio Pharmaceuticals, AlloVir, among others.
Hemophilia
Market
Hemophilia
Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key hemophilia
companies, including ApcinteX, ASC Therapeutics, Ultragenix Pharmaceutical, BioMarin Pharmaceutical, CSL Behring, Freeline Therapeutics, Genentech, Inc., Novo Nordisk, Pfizer, Sanofi, Shire, Spark Therapeutics, Amarna therapeutics, Asklepios BioPharmaceutical, Bayer, Belief Biomed, Bioverativ, Catalyst Biosciences, Centessa Pharmaceuticals, Chameleon Biosciences, Chia Tai Tianqing Pharmaceutical Group, Expression Therapeutics, GC Pharma, GeneVentiv, Intellia tx, OPKO Health, Sangamo Therapeutics, Staidson Beijing BioPharmaceuticals, UBI Pharma, uniQure , among others.
Hemophilia
Pipeline
Hemophilia Pipeline Insight – 2024
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key
Hemophilia companies, including Intellia tx, Amarna therapeutics, Expressi Ontherapeutics, GC Pharma, Chameleon Biosciences, Pfizer, UBI Pharma, GeneVentiv, Chia Tai Tianqing Pharmaceutical Group, Bayer, ASC Therapeutics, Catalyst Biosciences, Staidson Beijing BioPharmaceuticals, Spark Therapeutics, CSL Behring,
Sanofi, Novo Nordisk, Centessa Pharmaceuticals, OPKO Health, among others.
About
DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform
PharmDelve .
Contact Us
Shruti Thakur
[email protected]
+14699457679
Logo:
SOURCE DelveInsight Business Research, LLP

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- Manuka Honey Market Report 2024, Industry Growth, Size, Share, Top Compan...
- Modular Kitchen Market 2024, Industry Growth, Share, Size, Key Players An...
- Acrylamide Production Cost Analysis Report: A Comprehensive Assessment Of...
- Fish Sauce Market 2024, Industry Trends, Growth, Demand And Analysis Repo...
- Australia Foreign Exchange Market Size, Growth, Industry Demand And Forec...
- Cold Pressed Oil Market Trends 2024, Leading Companies Share, Size And Fo...
- Pasta Sauce Market 2024, Industry Growth, Share, Size, Key Players Analys...
Comments
No comment